Research map: Serum Glial Fibrillary Acidic Protein Dynamics, Disease Progression, and Therapy Response in Multiple Sclerosis

Back to the article

Papers in this map

  1. Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria · Alan J. Thompson · 2017 · 8286 citations · Cited by this paper
  2. Automated Speech Analysis to Identify Clinical, Anatomical, and Pathological Variants of Primary Progressive Aphasia · Jet M. J. Vonk · 2026 · 1 citation · Related
  3. Ocrelizumab versus Interferon Beta-1a in Relapsing Multiple Sclerosis · Stephen L. Hauser · 2016 · 2046 citations · Cited by this paper
  4. Neurological Manifestations in Adult Survivors of Ebola Virus Disease · 2026 · Related
  5. Ocrelizumab versus Placebo in Primary Progressive Multiple Sclerosis · Xavier Montalbán · 2016 · 1919 citations · Cited by this paper
  6. Musical Trick Alleviating Benign Essential Blepharospasm · 2026 · Related
  7. Serum Neurofilament light: A biomarker of neuronal damage in multiple sclerosis · Giulio Disanto · 2017 · 1195 citations · Cited by this paper
  8. Comorbidities and Outcomes in People With Functional Neurological Disorder · 2026 · Related
  9. Blood GFAP as an emerging biomarker in brain and spinal cord disorders · Ahmed Abdelhak · 2022 · 865 citations · Cited by this paper
  10. Neurological Teleconsultations in General Practice · 2026 · Related
  11. Serum neurofilament light chain for individual prognostication of disease activity in people with multiple sclerosis: a retrospective modelling and validation study · Pascal Benkert · 2022 · 645 citations · Cited by this paper
  12. Complete Remission of Cavin-4 Immunoglobulin G Rippling Muscle Disease After Rituximab Therapy · 2026 · Related
  13. Blood neurofilament light chain as a biomarker of MS disease activity and treatment response · Jens Kühle · 2019 · 584 citations · Cited by this paper
  14. Pathology and Genetics in a Global Cohort of Parkinsonian Disorders · 2026 · Related
  15. Serum neurofilament as a predictor of disease worsening and brain and spinal cord atrophy in multiple sclerosis · Christian Barro · 2018 · 550 citations · Cited by this paper
  16. Neurological Manifestations of Hantavirus Infection · 2026 · Related
  17. The Nine-Hole Peg Test as a manual dexterity performance measure for multiple sclerosis · Peter Feys · 2017 · 528 citations · Cited by this paper
  18. Plasma eMTBR-tau243 and %p-tau217 for Biological Staging of Alzheimer Disease · 2026 · Related
  19. Neurofilaments as biomarkers in neurological disorders — towards clinical application · Michael Khalil · 2024 · 439 citations · Cited by this paper
  20. Moving Beyond Legal Phobia to Medicolegal Advocacy in Neurology · 2026 · Related
  21. Validity of the timed 25-foot walk as an ambulatory performance outcome measure for multiple sclerosis · Robert Wayne Motl · 2017 · 423 citations · Cited by this paper
  22. Neurofilament protein in cerebrospinal fluid: a potential marker of activity in multiple sclerosis · Jan Lycke · 1998 · 321 citations · Cited by this paper
  23. Serum Glial Fibrillary Acidic Protein Compared With Neurofilament Light Chain as a Biomarker for Disease Progression in Multiple Sclerosis · Stephanie L. Meier · 2023 · 302 citations · Cited by this paper
  24. Serum GFAP as a biomarker for disease severity in multiple sclerosis · Ahmed Abdelhak · 2018 · 295 citations · Cited by this paper
  25. Harmonizing Definitions for Progression Independent of Relapse Activity in Multiple Sclerosis · Jannis Müller · 2023 · 216 citations · Cited by this paper
  26. Guidance for use of neurofilament light chain as a cerebrospinal fluid and blood biomarker in multiple sclerosis management · Mark Steven Freedman · 2024 · 200 citations · Cited by this paper
  27. Multiple sclerosis: emerging epidemiological trends and redefining the clinical course · Emilio Portaccio · 2024 · 167 citations · Cited by this paper
  28. Greater sensitivity to multiple sclerosis disability worsening and progression events using a roving versus a fixed reference value in a prospective cohort study · Ludwig Kappos · 2017 · 159 citations · Cited by this paper
  29. Blood neurofilament light levels predict non-relapsing progression following anti-CD20 therapy in relapsing and primary progressive multiple sclerosis: findings from the ocrelizumab randomised, double-blind phase 3 clinical trials · Amit Bar‐Or · 2023 · 104 citations · Cited by this paper
  30. Emerging Cerebrospinal Fluid Biomarkers of Disease Activity and Progression in Multiple Sclerosis · Anne Haney Cross · 2024 · 104 citations · Cited by this paper
  31. Neurofilament Light Chain Elevation and Disability Progression in Multiple Sclerosis · Ahmed Abdelhak · 2023 · 102 citations · Cited by this paper
  32. On the origin of Neurostatus · Ludwig Kappos · 2015 · 89 citations · Cited by this paper
  33. The Swiss Multiple Sclerosis Cohort-Study (SMSC): A Prospective Swiss Wide Investigation of Key Phases in Disease Evolution and New Treatment Options · Giulio Disanto · 2016 · 78 citations · Cited by this paper
  34. Serum Glial Fibrillary Acidic Protein and Neurofilament Light Chain Levels Reflect Different Mechanisms of Disease Progression under B‐Cell Depleting Treatment in Multiple Sclerosis · Pascal Benkert · 2024 · 61 citations · Cited by this paper
  35. Serum biomarkers at disease onset for personalized therapy in multiple sclerosis · Enric Monreal · 2024 · 49 citations · Cited by this paper
  36. Multiple sclerosis: two decades of progress · Bruce A C Cree · 2022 · 48 citations · Cited by this paper
  37. Serum glial fibrillary acidic protein predicts disease progression in multiple sclerosis · Evan Samuel Madill · 2024 · 36 citations · Cited by this paper
  38. Serum biomarker levels predict disability progression in patients with primary progressive multiple sclerosis · Nicolás Fissolo · 2023 · 25 citations · Cited by this paper
  39. GFAP and NfL as predictors of disease progression and relapse activity in fingolimod-treated multiple sclerosis · Aleksandra Maleska Maceski · 2025 · 21 citations · Cited by this paper

Source: OpenAlex (CC0)